Synthetic consortia of nanobody‐coupled and formatted bacteria for prophylaxis and therapy interventions targeting microbiome dysbiosis‐associated diseases and co‐morbidities. Issue 1 (21st December 2018)

• Record Type: Journal Article
• Authors: Timmis, Kenneth; Timmis, James Kenneth; Brüssow, Harald; Fernández, Luis Ángel
• Is Part Of: Microbial biotechnology. Volume 12:Issue 1(2019:Jan.)
• Page Start: 58
• Page End: 65
• Publication Date: 2018-12-21
• Subjects: Microbial biotechnology -- Periodicals; Biotechnology; Microbiology; 660.62
• DOI: 10.1111/1751-7915.13355
• Languages: English
• ISSNs: 1751-7915

Abstract

Abstract : Designed nanobody‐linked synthetic consortia for microbiota dysbiosis therapies. A. Nanobodies (Nb) are selected for specific antigens on target bacteria destined for a synthetic therapy consortium that may consist of two (B) or multiple (C) members. For the treatment of dysbiosis co‐morbidities requiring two functionally distinct consortia, these may be linked through a common member to generate a single bi‐functional microbiota therapy (D).